Launch
China approves first oral GLP-1 weight-loss pill
The Brief
- China has approved its first orally administered GLP-1 weight-loss drug.
- The approval permits Eli Lilly to sell its orforglipron pill in China.
- The source cites a projection that 630 million adults in China could be overweight or obese by 2050.
Why it matters
It adds an oral option to GLP-1 weight-loss treatments in a large market, which matters for researchers tracking obesity drug access and uptake.
Who’s affected
- researchers in obesity and metabolic disease
- health policy analysts
- #obesity
- #glp-1
- #drug-approval
- #china
- #eli-lilly
China has approved its first orally administered GLP-1 weight-loss drug, permitting Eli Lilly to sell its orforglipron pill in a market where 630 million adults could be overweight or obese by 2050.